A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study.

Abstract

Standard dose docetaxel is burdened by severe toxicity. Weekly schedules have been shown to be active as standard scheme with reduced side effects. In 20-30% of elderly patients (pts) the classic 6-week schedule induces grade 3/4 fatigue and other cumulative toxicities. We carried out this safety study in order to evaluate whether a modified weekly docetaxel schedule would improve the toxicity profile. Twenty-one untreated elderly (> or = 70 years) pts suffering from metastatic breast cancer were enrolled in the study. Pts were treated with a weekly dose of 35 mg/m2 docetaxel for 6 weeks, followed by a 2-week rest. Further cycles were performed with this modified schedule: docetaxel days 1, 8 and 15 every 29 days. All pts received at least the first cycle (6 weeks). A total of 261 doses were delivered. No toxic deaths occurred. The toxicity was mild: we recorded 1 episode of grade 3 neutropenia and severe asthenia in only 2 pts (10%). We recorded an overall response rate of 33% (1 CR, 6 PR). Our data showed a reduced incidence of severe asthenia (2/21), obtained with a light modification of a weekly docetaxel schedule.

• Authors: R Maisano, M Mare, N Caristi, G Chiofalo, M Picciotto, R Carboni, A Mafodda, F La Torre
• Journal: Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 17 Issue 2 Pg. 242-6 (Apr 2005) ISSN: 1120-009X [Print] England
• PMID: 15920913 (Publication Type: Journal Article)

Chemical References

• Taxoids
• Docetaxel

Topics

• Age Factors
• Aged
• Bone Neoplasms (secondary)
• Breast Neoplasms (drug therapy, mortality, pathology)
• Docetaxel
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Geriatric Assessment
• Humans
• Liver Neoplasms (secondary)
• Lung Neoplasms (secondary)
• Lymphatic Metastasis
• Maximum Tolerated Dose
• Neoplasm Metastasis (drug therapy)
• Neoplasm Staging
• Prospective Studies
• Risk Assessment
• Skin Neoplasms (secondary)
• Survival Analysis
• Taxoids (administration & dosage, adverse effects)
• Treatment Outcome